TDP-43 normally resides in the nucleus, where it has several roles in maintaining neuronal health and function. In most cases of ALS, the protein leaves the nucleus and aggregates in the cytoplasm. The research group had previously shown that sudden stress can prevent TDP-43 from forming the pairs or small groups in which it normally operates, causing individual molecules to be re-exported from the nucleus as dysfunctional material. The team’s new experiments traced what happens when these unpaired TDP-43 molecules enter the cytoplasm. They physically interact with TBK1, a sensor protein known to activate autophagy and one whose gene mutations can cause inherited ALS.

Autophagy is the process by which faulty proteins are collected in small vesicles and digested. When Sakai inhibited that process, the elimination of TDP-43 was not blocked in his experiments, leading the researchers to investigate a parallel mechanism. TBK1 also activates a signal mediated by interferon beta that can be perceived by the neuron producing it and by neighboring cells. Neurons that received the signal increased production of the immunoproteasome, a protein-degrading system that normally helps immune cells disassemble virus components and display peptide fragments on their surfaces. In the experimental models, increased immunoproteasome activity broke down TDP-43 before it aggregated. The finding shows that motor neurons can deploy this system in response to abnormal proteins, in addition to its better-established role in immune cells during viral infection.

Evidence for the pathway came from multiple experimental systems. Cultured neurons and human stem cell-derived motor neurons were used to examine the sequence connecting TDP-43 with TBK1, interferon beta and immunoproteasome activity, while mouse experiments provided additional support. The researchers also analyzed spinal-cord samples donated after death by people with ALS. The receptor for the interferon-beta signal was present in significantly lower quantities in motor neurons from the ALS samples than in samples from people without ALS. This tissue-level difference is an association: the study did not establish that reduced receptor abundance causes TDP-43 accumulation or ALS. Cultured-cell and mouse findings also cannot by themselves demonstrate clinical benefit in patients.

The researchers described the pathway as a possible therapeutic avenue, but they cautioned that directly administering interferon beta does not appear practical for ALS. Interon beta has been used in treatments for other conditions, but it triggers many biological responses, and its severe side effects cannot be ignored. Yamanaka said the group’s next objective is to identify other compounds that can activate the immunoproteasome in motor neurons. Sakai said the pathway’s true therapeutic potential remains to be established. The study therefore identifies a mechanism for further investigation rather than a proven intervention: the reported findings come from neuronal cultures, mice and postmortem human tissue, and no treatment efficacy or safety was evaluated in people with ALS.

Subject of Research: Mechanisms of TDP-43 clearance and immunoproteasome activation in ALS models

Article Title: A new path(way) for ALS research opens

Article References: A new path(way) for ALS research opens. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: ALS, TDP-43, TBK1, interferon beta, immunoproteasome, motor neurons, protein aggregation, stem cell-derived neurons, mouse models, Nagoya University, path, research

The proteasome is a massive 2.5-megadalton complex whose 20S catalytic core is capped by 19S regulatory particles that unfold ubiquitinated substrates and thread them into the destruction chamber. A narrow channel of roughly 15 angstroms in the alpha ring forces every substrate to enter in an extended, unfolded state. Structural studies of proteases bound to their substrates have long suggested that the polypeptide chain must flatten into an extended beta-strand conformation inside the catalytic groove, and modern inhibitors such as carfilzomib and bortezomib mimic exactly that geometry. What remained unclear was whether the conformation a substrate region adopts before it reaches the active site leaves any detectable signature on where the cuts actually fall.

Previous work on proteasomal specificity has focused almost entirely on sequence: the beta5 catalytic subunit favors hydrophobic residues, beta2 prefers basic ones, and the immunoproteasome’s swapped subunits further tune those preferences. But sequence motifs alone cannot explain why cleavage appears biased toward particular structural contexts. The researchers asked a deceptively simple question: how much cleavage signal survives when amino-acid identity is stripped away entirely, leaving only information about whether each residue sits in a helix, a beta-strand, or a coil?

To find out, the team first mined a corpus of 1,505 non-redundant human and viral protein structures from the Protein Data Bank, all resolved at 2.5 angstroms or better. They scored every residue with established sequence-based cleavage predictors, including NetChop 20S, NetChop C-term, ProteaSMM-C, and ProteaSMM-I, then compared the secondary-structure composition of the top 10 percent of predicted cleavage sites against the background composition of the whole corpus. The result was striking: high-confidence predicted cleavage sites were consistently enriched in beta-strand, or extended, conformations and depleted in coil-like regions. The beta-strand signal peaked near the cleavage site itself, forming a bell-shaped profile that faded with distance, and it was even stronger for predictors trained on immunoproteasome and MHC class I ligand data.

The reciprocal pattern appeared at unfavored sites. There, coils were enriched while helices and beta-strands were underrepresented relative to expectation. Crucially, the same tendencies held when the researchers analyzed true experimental cleavage sites from a 20-protein digestion dataset combining published in vitro data, and they held whether secondary structure was predicted from sequence by NetSurfP-3.0 or assigned directly from crystallographic coordinates by STRIDE. A protein-level analysis reinforced the point: mean predicted coil content correlated inversely with mean predicted cleavage probability across the 1,505-protein corpus and across 22 experimental digestion maps, suggesting the association is not an artifact of residue-level statistical non-independence.

The team then went a step further and built a machine learning model that saw no amino acids at all. Their proof-of-concept classifier, dubbed SSO-8, represented each candidate cleavage site as an eight-residue window spanning positions P4 to P4′ on either side of the scissile bond, encoded solely as 64 eight-state secondary-structure probabilities predicted by NetSurfP-3.0. Trained on the 20-protein digestion dataset, which contains 1,215 experimentally determined cleavage sites, the final SSO-8 model was a linear support-vector machine selected by protein-grouped cross-validation. On held-out validation benchmarks derived from 16 HIV-derived peptides, SSO-8 achieved an area under the ROC curve of 0.649 on the constitutive proteasome dataset and 0.737 on the immunoproteasome dataset.

Those numbers become remarkable in context. A matched sequence-only control, trained with the identical protocol but using full one-hot amino-acid encodings, reached AUC values of 0.674 and 0.736 on the same benchmarks, and paired statistical tests found no significant difference between the structure-only and sequence-only models. In other words, secondary structure alone captured nearly the same cleavage signal as complete amino-acid identity, while using 2.5-fold less input information. On the immunoproteasome benchmark, SSO-8 even edged out the widely used NetChop 20S predictor, which reached an AUC of 0.711, and matched NetChop C-term at 0.731.

To test whether structural information adds anything beyond sequence, the researchers constructed hybrid position-specific scoring matrices, or PSSMs, that aggregated predictions from multiple methods. Adding SSO-8 to a sequence-only ensemble nudged the immunoproteasome benchmark AUC from 0.781 to 0.797, and the best five-method ensemble reached 0.806. The improvement was directionally consistent but not statistically significant, with a paired permutation p-value of 0.30, so the authors are careful to present it as suggestive rather than conclusive. Still, the pattern supports the idea that local backbone conformation carries cleavage information partly orthogonal to sequence motifs.

The team also ran a rigorous audit for data leakage. Pairwise Needleman-Wunsch alignments confirmed that no protein pair between the two training subsets, or between the training set and the validation peptides, exceeded the standard 30 percent identity threshold for functional relatedness. And because the PSSM octamer labels were derived purely from predicted scores rather than experimental annotations, experimental data from training proteins could not circularly inflate the corpus-based results. A post hoc analysis added another intriguing layer: beta-strand frequency at true immunoproteasome cleavage sites was 32.5 percent, significantly higher than the 18.7 percent observed at constitutive cleavage sites, indicating that the two proteasome types carry distinguishable structural signatures.

Mechanistically, the authors propose that strand-like geometry may simply reflect compatibility with the extended conformation the proteasome demands of its substrates, rather than selection for intact native beta-strands before engagement. The signal was consistently stronger for the immunoproteasome, the isoform induced by interferon-gamma during inflammation that specializes in producing ligands for MHC class I presentation. Because proteasomal cleavage generates the C-terminal anchor residue of presented peptides, the researchers hypothesize that this beta-strand bias may steer the immunoproteasome’s output toward structurally constrained regions of proteins, where escape mutations are less tolerated by the virus or tumor. If confirmed, incorporating structural features into next-generation cleavage predictors could improve epitope and neoantigen discovery for vaccine development and cancer immunotherapy, though the authors caution that their model was trained on limited in vitro data lacking cellular context, and that protein language models may offer an even richer structural representation for future work.

Subject of Research: Association between substrate local secondary structure and proteasomal cleavage propensity

Article Title: Substrate secondary structure is associated with proteasomal cleavage propensity

Article References: Gutierres, M. D. B. B., Beruldsen, F., Antunes, D. A., & Vieira, G. F. (2026). Substrate secondary structure is associated with proteasomal cleavage propensity. Frontiers in Bioinformatics, 6, Article 1730535. https://doi.org/10.3389/fbinf.2026.1730535

Image Credits: AI Generated

DOI: 10.3389/fbinf.2026.1730535

Keywords: proteasome, immunoproteasome, secondary structure, beta-strand, machine learning, MHC class I, T-cell epitopes, cleavage prediction, immunoinformatics, neoantigen, Protein Data Bank, NetSurfP

The patient’s disease was discovered almost by accident. During a routine health examination in April 2022, chest computed tomography revealed an irregular mass in the apical segment of the right upper lobe, measuring approximately 5.9 by 5.0 centimeters at its largest cross-section. The lesion sat dangerously close to the mediastinal pleura and the right brachiocephalic vein, and imaging suggested metastatic involvement of right hilar and mediastinal lymph nodes. A percutaneous biopsy confirmed squamous cell carcinoma, one of the two major subtypes of non-small cell lung cancer, supported by a characteristic immunohistochemical profile including strong staining for P63 and cytokeratin markers with negative TTF-1 and NapsinA. Under the eighth edition of the UICC/AJCC staging system, the tumor was classified as T3N2M0, placing it firmly in stage IIIB territory, a stage at which a large proportion of patients are considered inoperable at diagnosis.

Beginning in July 2022, the patient received three 21-day cycles of albumin-bound paclitaxel and cisplatin alongside 1200 milligrams of sugemalimab, an IgG4 monoclonal antibody that blocks the interaction between programmed death-ligand 1 and its receptors on T cells. The only reported toxicity during this period was grade I nausea, a remarkably mild profile for such an aggressive preoperative regimen. After two cycles, a follow-up CT scan showed the tumor had shrunk to roughly 4.8 by 3.7 centimeters, but more striking was the change in its internal character. The soft tissue density had decreased so substantially that the lesion now appeared as a cavity surrounded by minimal ground-glass opacity. By the formal RECIST 1.1 criteria, this counted only as stable disease, a reminder that conventional imaging metrics can dramatically understate the biological impact of immunotherapy, which works by triggering immune infiltration and tissue remodeling rather than rapid tumor collapse.

Surgery took place on October 10, 2022, in the form of video-assisted thoracic surgery with right upper lobectomy and systematic lymph node dissection. The pathological examination told a story the CT scans had only hinted at. The lung interstitium showed extensive fibrosis, lymphocytic infiltration, aggregates of multinucleated giant cells, and small focal calcifications, the archaeological traces of a tumor that had been dismantled by the immune system. Microscopy revealed no definite residual cancer anywhere in the specimen. The bronchial margins were clear, the visceral pleura was uninvolved, and none of the dissected lymph nodes contained metastatic disease or even treatment-related fibrosis, yielding a pathological stage of ypT0N0. The patient then completed one additional cycle of immunochemotherapy after surgery, followed by a planned year of sugemalimab maintenance monotherapy, a strategy embedded in the team’s prospective perioperative chemoimmunotherapy trial registered as NCT04941417.

The case sits within a rapidly shifting treatment landscape. For decades, surgery followed by adjuvant chemotherapy was the standard approach for resectable stage II to III non-small cell lung cancer, yet adjuvant chemotherapy improved five-year overall survival by only about five percentage points. The introduction of immune checkpoint inhibitors changed that calculus. The CheckMate 816 trial, the first phase 3 study of neoadjuvant chemoimmunotherapy in stage IB to IIIA disease, demonstrated that adding the anti-PD-1 antibody nivolumab to chemotherapy raised the pathological complete response rate from 2.2 percent to 24.0 percent and extended event-free survival from 20.8 to 31.6 months. More recently, the KEYNOTE-671 trial tested perioperative pembrolizumab in stage IIA to IIIB patients and met both of its dual primary endpoints, with median event-free survival of 47.2 months compared to 18.3 months with placebo, and a clear overall survival advantage. Despite lingering debates over whether patients who achieve a complete pathological response still need postoperative immunotherapy, neoadjuvant chemoimmunotherapy is now firmly embedded in clinical practice.

What distinguishes this report is the effort to understand why this particular patient responded so completely, and the investigators approached that question from several angles simultaneously. Baseline immunohistochemistry using the Dako 22C3 assay showed a tumor proportion score for PD-L1 of just 5 percent, a level generally considered low and, on its own, a poor predictor of benefit from checkpoint blockade. That finding underscores a persistent problem in the field: PD-L1 expression alone fails to capture the complexity of immunotherapy response, particularly in squamous histology, where the immune landscape differs markedly from that of lung adenocarcinoma. Previous work has shown that lung squamous cell carcinoma carries a predominantly immunocompromised signature, including heavy infiltration of M2-polarized macrophages into tumor islets and downregulation of complement cascade genes.

To probe that microenvironment directly, the team employed multiplex immunofluorescence on baseline and post-treatment specimens, using DAPI to label all cell nuclei, pan-cytokeratin to mark cancer cells, CD68 as a pan-macrophage marker, CD86 and IRF5 to identify pro-inflammatory M1 macrophages, and CD163 and CD206 to flag immunosuppressive M2 macrophages. The results painted a picture of an immune landscape tilted toward tumor promotion. In the baseline primary tumor, M1 cells numbered 11 per square millimeter while M2 cells reached 77 per square millimeter. After treatment, the resected tumor bed showed a single M1 cell against 103 M2 cells per square millimeter, yet the resected lymph node told a different story, with the M1-to-M2 density gap narrowing to a difference of 22 per square millimeter compared to 102 in the tumor bed. The authors interpret the lymph node finding as evidence of a pro-anti-tumor environment in the tumor-draining lymph nodes, consistent with the favorable clinical outcome. Preclinical studies support this reading: anti-PD-L1 antibodies have been shown to remodel the macrophage compartment toward a more proinflammatory phenotype through interferon-gamma signaling, and sugemalimab specifically has been reported to upregulate M1 macrophages while suppressing myeloid-derived suppressor cells.

The investigators also examined the immunoproteasome, a specialized form of the proteasome complex whose catalytic subunits PSMB-8, PSMB-9, and PSMB-10 are induced by interferon-gamma and tumor necrosis factor-alpha under inflammatory conditions and are implicated in antigen presentation, tumor invasion, and lymph node metastasis. Using quantitative H-score analysis with QuPath software, they found that expression of all three subunits peaked in the resected lymph node samples. PSMB-8 scored 195 in the primary lesion, 239 in the lymph node, and 191 in the tumor bed; PSMB-9 scored 145, 155, and 126 respectively; and PSMB-10 scored 181, 200, and 197. When binned into low, intermediate, and high categories, PSMB-9 and PSMB-10 expression proved broadly similar across the three sites, with only PSMB-10 appearing meaningfully elevated in the lymph nodes. The authors caution that a single case cannot establish mechanism, but they suggest that PSMB-8 inhibition and its relationship to anti-tumor outcomes in tumor-draining lymph nodes merit systematic exploration.

Perhaps the most clinically translatable finding came from the liquid biopsy. Using next-generation sequencing targeting 425 tumor-related genes on plasma samples collected before treatment and after one cycle of neoadjuvant therapy, the team measured a baseline tumor mutational burden of 4.1 mutations per megabase with six detectable somatic mutations. After a single cycle of chemoimmunotherapy, circulating tumor DNA fell to zero, a complete molecular clearance that preceded both the radiographic response and the pathological one. Circulating tumor DNA has emerged as a promising non-invasive marker of molecular residual disease, capable of signaling recurrence or metastasis before standard imaging can detect it. In this case, the early clearance complemented the imaging assessment as a predictor of treatment response, and the authors argue that ctDNA surveillance could eventually help determine which patients with complete pathological responses can safely forgo or shorten adjuvant therapy, a question that remains unresolved.

The report’s authors, led by Ziyi Xu and Puyuan Xing of the National Cancer Center in Beijing, are careful to frame the findings appropriately. A single patient cannot prove that sugemalimab plus chemotherapy is superior to alternatives, and the biomarker observations, from macrophage polarization to immunoproteasome expression, are hypothesis-generating rather than definitive. Yet the case illustrates a broader convergence in oncology: treatment decisions increasingly informed not just by what a tumor looks like under the microscope, but by the molecular conversation it conducts with the immune system. The patient, a heavy smoker with a 30-pack-year history whose tumor expressed low levels of PD-L1, would have been difficult to flag as a responder using any single conventional marker. It was the combination of pathological response, molecular clearance in the blood, and microenvironmental shifts across three tissue compartments that revealed the depth of the treatment effect. As the investigators note, PD-L1 status, circulating tumor DNA dynamics, and tumor microenvironment characteristics together form a set of hallmark features indicative of clinical outcomes, and larger prospective studies will be needed to determine which of these signals can reliably guide therapy for the many stage IIIB patients whose tumors remain stubbornly inoperable.

Subject of Research: Neoadjuvant anti-PD-L1 immunotherapy combined with chemotherapy for stage IIIB lung squamous cell carcinoma and associated predictive biomarkers

Article Title: Case report of neoadjuvant treatment with sugemalimab combined with platinum-based doublet chemotherapy in stage IIIB lung squamous cell carcinoma and research in potential biomarkers

Article References: Xu, Z., Chen, D., Xie, T., Shao, K., Li, Y., Ying, J., Li, J., & Xing, P. (2026). Case report of neoadjuvant treatment with sugemalimab combined with platinum-based doublet chemotherapy in stage IIIB lung squamous cell carcinoma and research in potential biomarkers. Heliyon, 12(15), Article e45473. https://doi.org/10.1016/j.heliyon.2026.e45473

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45473

Keywords: lung squamous cell carcinoma, sugemalimab, neoadjuvant chemoimmunotherapy, pathological complete response, PD-L1, circulating tumor DNA, tumor mutational burden, tumor microenvironment, macrophage polarization, immunoproteasome, non-small cell lung cancer, biomarkers

The research, led by Zhenfang Shan, Jieqiong Li, and Zhaohui Tong of Beijing Chao-Yang Hospital, Capital Medical University, took a proteomics approach—measuring large panels of proteins in plasma rather than relying on clinical scores alone. The team analyzed plasma samples from 196 patients with ARDS, 100 pulmonary patients who did not have ARDS, and 100 healthy controls. Using mass spectrometry-based profiling and statistical tools including partial least squares-discriminant analysis, the researchers searched for proteins that consistently separated ARDS patients from the comparison groups.

The signal that emerged was striking. Pathways related to the proteasome—the cellular machine that shreds damaged or unwanted proteins into small peptides—were significantly activated in ARDS patients. Of particular interest was the immunoproteasome, a specialized version of the proteasome found in immune cells that processes proteins for presentation to the immune system. Rather than a single protein, the researchers found that a panel of seven immunoproteasome subunits collectively carried a robust diagnostic fingerprint of the syndrome.

To turn that observation into a practical tool, the team built a diagnostic model using LASSO regression, a machine learning technique that selects the most informative predictors while guarding against overfitting. Trained on 277 samples, the seven-subunit panel achieved an area under the receiver operating characteristic curve (AUC) of 0.908, indicating strong discriminatory power. Critically, the model held up in an independent validation cohort of 119 samples, where it achieved an AUC of 0.890. That kind of consistency across separate cohorts is what separates promising biomarkers from statistical artifacts, and it suggests the panel could distinguish ARDS from other serious lung conditions at the bedside.

The researchers did not stop at diagnosis. They traced where the biomarkers came from, examining bronchoalveolar lavage fluid—the liquid sampled from deep within the lungs of patients—and confirming that the proteasome signature reflected genuine biological activity in the injured lung rather than a distant systemic echo. They then moved into an animal model, inducing ARDS-like lung injury in mice with lipopolysaccharide, a component of bacterial cell walls that triggers intense inflammation.

In the mouse model, one subunit stood out: PSMB8, also known as the low molecular mass polypeptide 7 or LMP7, a catalytic subunit unique to the immunoproteasome. PSMB8 expression was upregulated in lung tissue after injury, and single-cell and lineage analyses indicated that the protein was produced primarily by monocytes and macrophages—the scavenger immune cells that swarm into inflamed lungs and often drive much of the collateral tissue damage. The degree of PSMB8 elevation correlated with disease severity, tying the molecular marker to clinical outcomes.

The therapeutic experiments were the most consequential part of the study. When the researchers inhibited PSMB8 pharmacologically, or deleted the Psmb8 gene in mice, the results were consistent: lung injury was reduced, inflammation was blunted, and respiratory dysfunction improved. Measurements of lung mechanics, including resistance and compliance, along with wet-to-dry weight ratios that quantify fluid accumulation in the lung, all pointed toward meaningful protection when the immunoproteasome subunit was removed from the picture.

The mechanism behind that protection appears to lie in macrophage behavior. PSMB8 deficiency suppressed M1-like macrophage polarization—the pro-inflammatory state that macrophages adopt when they are pumping out cytokines and reactive molecules that, while meant to fight pathogens, can devastate surrounding tissue. Intriguingly, the researchers found that this shift was accompanied by alterations in lipid metabolic pathways, hinting that the immunoproteasome influences not just protein degradation but also the metabolic programming that determines whether macrophages soothe or scorch the lung.

The implications are twofold. Diagnostically, a blood test built on seven proteasome subunits could complement existing tools such as the Sequential Organ Failure Assessment and APACHE II scores, offering an objective, biologically grounded way to identify ARDS early—potentially before patients require invasive mechanical ventilation. Therapeutically, PSMB8 joins a growing list of immune-focused targets for a syndrome that currently lacks a specific drug; treatment today is largely supportive, centered on ventilator management and care of the underlying cause.

Caveats remain. The therapeutic results come from a preclinical mouse model, and the authors themselves emphasize that PSMB8 is a promising but still preclinically validated target that warrants further investigation. Translating proteasome inhibition into safe human therapy will require careful work, since the immunoproteasome plays normal roles in immune surveillance. Still, the convergence of a clinically validated biomarker panel with a mechanistically supported drug target—grounded in more than 300 patient samples and confirmed in animal studies—represents an unusually coherent translational package for a syndrome that has long resisted both early detection and targeted treatment.

Subject of Research: A proteasome subunit-based biomarker panel for early diagnosis of acute respiratory distress syndrome and therapeutic targeting of PSMB8

Article Title: Proteasome subunit-based biomarker panel for early diagnosis of acute respiratory distress syndrome and therapeutic targeting of PSMB8 in a mouse model

Article References: Shan, Z., Zhang, H., Ma, J., Gou, Y., Li, J., & Tong, Z. (2026). Proteasome subunit-based biomarker panel for early diagnosis of acute respiratory distress syndrome and therapeutic targeting of PSMB8 in a mouse model. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08645-6

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08645-6

Keywords: ARDS, biomarkers, proteasome, immunoproteasome, PSMB8, macrophage polarization, plasma proteomics, LASSO regression, lung injury, intensive care, diagnostic panel, lipopolysaccharide mouse model

The study exploited an unusual natural experiment: fourteen HeLa cell line variants, collected from thirteen laboratories around the world, that have drifted genetically over decades of independent culture. These lines display strikingly different behaviors — some grow faster, some are more invasive, and some are far more susceptible to Salmonella infection — despite descending from the same original tumor. Because this genetic drift generated a diverse landscape of genotypes, proteomes, and phenotypes without any deliberate manipulation, the panel serves as a natural perturbation system, ideal for tracing how molecular differences cascade into functional differences. Previous work on these cells had profiled their genomes, transcriptomes, and total proteomes, but never their protein complexes, leaving a critical gap between molecular measurements and cellular behavior.

The team closed that gap using SEC-SWATH-MS, a technique that physically separates proteins by size before quantifying them by mass spectrometry. Because protein complexes elute from the size-exclusion column at positions corresponding to their molecular weight, while monomeric proteins appear at their individual sizes, the method physically distinguishes the assembled and unassembled fractions of the same protein. Applying this approach to the two most behaviorally divergent lines — the invasive, infection-prone HeLa CCL2 and the faster-growing HeLa Kyoto — across 420 mass spectrometry runs, the researchers generated a quantitative matrix covering 7,175 proteins. A computational toolkit called SECAT then translated these co-elution profiles into six distinct metrics per protein: total abundance, assembled abundance, monomer abundance, complex abundance, interactor abundance, and interactor ratio.

The most striking finding concerns a long-standing hypothesis in molecular biology: that protein complex assembly buffers cells against variation in gene copy number and transcription. Earlier studies had inferred this buffering indirectly from bulk correlations between mRNA and protein levels, but never demonstrated it by physically separating the two states of the same molecule. The new data provide exactly that direct evidence. For proteins present in both monomeric and assembled forms — the so-called paired state — the monomeric fraction tracked gene dosage far more tightly than the assembled fraction. Spearman correlations with copy number variation were 0.322 for monomers versus 0.198 for assembled proteins, and with mRNA abundance 0.574 versus 0.484, differences that reached statistical significance. In other words, when copy number or transcription fluctuates, the excess unassembled subunits appear to be selectively degraded by cellular quality-control pathways, while the functional complex-bound pool remains stable.

This buffering is not a passive curiosity but appears central to cellular fitness. When the researchers cross-referenced their protein classifications with CRISPR gene dependency scores from the DepMap project, they found that paired-state proteins — those subject to assembly buffering — are significantly more essential for cell survival than proteins detected only as monomers, with a p-value of 1.35 × 10⁻²⁹ and median dependency probabilities of 0.065 versus 0.032. Complex assembly, the authors conclude, functions as a protective shield insulating core cellular machinery from the noise of genetic drift. This is precisely the kind of mechanistic insight that total protein abundance measurements, however accurate, cannot deliver, because they average together the monomeric and complexed pools into a single number.

To capture additional layers of protein function beyond structure, the team deployed two network-based inference algorithms. VIPER infers transcription factor activity from transcriptomic data by measuring the enrichment of a regulator’s known target genes among differentially expressed transcripts. VESPA applies the same enrichment logic to phosphoproteomic data, estimating kinase and phosphatase activities from the phosphorylation states of their substrates. Applied to the HeLa panel, msVESPA identified 73 of 549 kinases and phosphatases as differentially active between CCL2 and Kyoto cells, while msVIPER flagged 2,009 differentially active regulatory proteins out of 6,156 tested. The researchers then validated these inferred activities against three independent reference datasets: CRISPR dependency scores, subcellular localization annotations from the Human Protein Atlas, and microRNA perturbation responses, confirming that the inferences prioritize essential genes, map to coherent cellular structures, and track phenotypic outcomes.

Bringing all three layers together through network diffusion analysis, the study surfaced two major mechanistic themes distinguishing the cell lines. The first centers on invasion and infection. The actin-nucleating Arp2/3 complex, which drives the formation of invadopodia — protrusive structures that both degrade surrounding tissue and admit bacterial entry — is more abundant in CCL2 cells. Critically, the regulatory proteins WIPF1 and WIPF2, which control Arp2/3 activation through the WASP family, show a decisive stoichiometric shift: WIPF1 predominates in CCL2, promoting invadopodium initiation, while WIPF2 dominates in Kyoto, where it blocks initiation and preserves a stable cortical actin network. This WIPF1/WIPF2–Arp2/3 axis plausibly explains why CCL2 cells are both more invasive and more susceptible to Salmonella, since the same membrane-ruffling machinery serves pathogen and tumor cell alike.

The second theme involves immune adaptation. SECAT revealed that while total proteasome subunit abundance barely differs between the lines, CCL2 cells assemble both constitutive proteasomes and immunoproteasomes — an inflammatory variant that generates different peptide fragments for MHC class I antigen presentation. Kyoto cells, by contrast, rely exclusively on the constitutive form, with higher levels of proteasome assembly chaperones. Such an immunoproteasome switch, invisible to conventional abundance profiling because PSMB8 and PSMB9 showed no significant total-abundance changes, represents a form of immune phenotypic plasticity with obvious implications for how tumor cells evade immune surveillance. Similar abundance-invisible mechanisms appeared throughout the data: the IQGAP2–CDC42 scaffolding complex and COP9 signalosome–DDB1/2 supercomplexes differed in stoichiometry between the lines while neither partner changed detectably in total amount.

The broader significance of the work lies in its reframing of what a protein measurement should mean. A protein, the authors argue, is not a single attribute but a bundle of context-dependent states — its abundance, its assembly, its phosphorylation, and its regulatory activity — each captured by a different molecular network. By reconstructing context-specific protein-protein interaction, kinase-substrate, and gene regulatory networks from the data itself and propagating signals across them, the framework identifies functional drivers rather than abstract variance components, complementing latent-factor approaches such as MOFA. The nominated mechanisms are directly testable: LIMK1 activity can be probed with kinase assays, SCF complex reconfiguration by co-immunoprecipitation, and the WIPF1/WIPF2 ratio by live-cell imaging of invadopodia. The authors acknowledge limitations — the approach still demands substantial sample and instrument time, and reference databases remain biased toward well-studied biology — but they envision the framework as a stepping stone toward artificial intelligence virtual cell models capable of adaptive, mechanism-based predictions of cell state. For now, the message is clear: to understand why two genetically similar cells behave so differently, look past how much protein they make, and ask what that protein is actually doing.

Subject of Research: Multi-omics inference of protein complex assembly and activity states as determinants of cellular phenotypic variability

Article Title: Complex assembly and activity states as multifaceted protein attributes explaining phenotypic variability

Article References: Rosenberger, G., Xue, P., Bludau, I., Martelli, C., Williams, E., Collins, B. C., Califano, A., Liu, Y., & Aebersold, R. (2026). Complex assembly and activity states as multifaceted protein attributes explaining phenotypic variability. Molecular Systems Biology. https://doi.org/10.1038/s44320-026-00228-3

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00228-3

Keywords: proteomics, protein complexes, multi-omics, SEC-SWATH-MS, SECAT, HeLa cells, protein activity, network diffusion, copy number variation, immunoproteasome, invadopodia, systems biology